{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:02:09Z","timestamp":1762606929321},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T00:00:00Z","timestamp":1488240000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s00120-017-0342-3","type":"journal-article","created":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T12:04:25Z","timestamp":1488283465000},"page":"486-491","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Nebenwirkungen der Immun-Checkpoint-Inhibitoren"],"prefix":"10.1007","volume":"56","author":[{"given":"S.","family":"Foller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Oppel-Heuchel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Fetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-O.","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,28]]},"reference":[{"key":"342_CR1","unstructured":"http:\/\/www.endokrinologie.net\/files\/download\/glukokortikoide-notfallausweis.pdf . Zugegriffen: 16. Dezember 2016"},{"key":"342_CR2","unstructured":"KEYTRUDA(R) https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=9333c79b-d487-4538-a9 \u202ff0-71b91a02b287. Zugegriffen: 16. Dezember 2016"},{"key":"342_CR3","unstructured":"OPDIVO(R) https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394#ID_5afbcf66-4c48-4ad9-8bc7-b40c7014986c . Zugegriffen: 16. Dezember 2016"},{"key":"342_CR4","unstructured":"TECENTRIQ(R) https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=6fa682c9-a312-4932-9831-f286908660ee . Zugegriffen: 16. Dezember 2016"},{"key":"342_CR5","doi-asserted-by":"crossref","first-page":"e1209615","DOI":"10.1080\/2162402X.2016.1209615","volume":"5","author":"E Arriola","year":"2016","unstructured":"Arriola E, Wheater M, Lopez MA, Thomas G, Ottensmeier C (2016) Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis. Oncoimmunology 5:e1209615","journal-title":"Oncoimmunology"},{"key":"342_CR6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","volume":"60","author":"VR Belum","year":"2016","unstructured":"Belum VR, Benhuri B, Postow MA et al (2016) Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 60:12\u201325","journal-title":"Eur J Cancer"},{"key":"342_CR7","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","volume":"101","author":"SR Bornstein","year":"2016","unstructured":"Bornstein SR, Allolio B, Arlt W et\u00a0al (2016) Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J\u00a0Clin Endocrinol Metab 101:364\u2013389","journal-title":"J Clin Endocrinol Metab"},{"key":"342_CR8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","volume":"45","author":"TK Eigentler","year":"2016","unstructured":"Eigentler TK, Hassel JC, Berking C et al (2016) Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 45:7\u201318","journal-title":"Cancer Treat Rev"},{"key":"342_CR9","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","volume":"39","author":"M Johncilla","year":"2015","unstructured":"Johncilla M, Misdraji J, Pratt DS et al (2015) Ipilimumab-associated hepatitis: clinicopathologic characterization in a\u00a0series of 11 cases. Am J Surg Pathol 39:1075\u20131084","journal-title":"Am J Surg Pathol"},{"key":"342_CR10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12882-016-0408-2","volume":"17","author":"K Jung","year":"2016","unstructured":"Jung K, Zeng X, Bilusic M (2016) Nivolumab-associated acute glomerulonephritis: a\u00a0case report and literature review. BMC Nephrol 17:188","journal-title":"BMC Nephrol"},{"key":"342_CR11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S et al (2016) Immune-related adverse events with immune checkpoint blockade: a\u00a0comprehensive review. Eur J Cancer 54:139\u2013148","journal-title":"Eur J Cancer"},{"key":"342_CR12","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.jaad.2012.12.963","volume":"69","author":"K Minkis","year":"2013","unstructured":"Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME (2013) The risk of rash associated with ipilimumab in patients with cancer: a\u00a0systematic review of the literature and meta-analysis. J\u00a0Am Acad Dermatol 69:e121\u2013e128","journal-title":"J Am Acad Dermatol"},{"key":"342_CR13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/ckj\/sfw024","volume":"9","author":"N Murakami","year":"2016","unstructured":"Murakami N, Borges TJ, Yamashita M, Riella LV (2016) Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin Kidney\u00a0J 9:411\u2013417","journal-title":"Clin Kidney J"},{"key":"342_CR14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2005","author":"J Naidoo","year":"2016","unstructured":"Naidoo J, Wang X, Woo KM et al (2016) Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J\u00a0Clin Oncol. doi: 10.1200\/JCO.2016.68.2005","journal-title":"J Clin Oncol"},{"key":"342_CR15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc1505197","volume":"373","author":"M Nishino","year":"2015","unstructured":"Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaiya NH (2015) Anti-PD-1-related pneumonitis during cancer immunotherapy. N\u00a0Engl J Med 373:288\u2013290","journal-title":"N Engl J Med"},{"issue":"5","key":"342_CR16","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00120-016-0109-2","volume":"55","author":"H Oppel-Heuchel","year":"2016","unstructured":"Oppel-Heuchel H, Grimm MO (2016) Therapy monitoring and management of adverse events in PD-1\/PD-L1 immune checkpoint inhibition. Urologe\u00a0A 55(5):677\u2013690","journal-title":"Urologe A"},{"key":"342_CR17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s13244-014-0335-3","volume":"5","author":"S Palmucci","year":"2014","unstructured":"Palmucci S, Roccasalva F, Puglisi S et\u00a0al (2014) Clinical and radiological features of idiopathic interstitial pneumonias (IIPs): a\u00a0pictorial review. Insights Imaging 5:347\u2013364","journal-title":"Insights Imaging"},{"key":"342_CR18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","volume":"35","author":"MA Postow","year":"2015","unstructured":"Postow MA (2015) Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 35:76\u201383","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"342_CR19","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a\u00a0single-arm, multicentre, phase 2 trial. Lancet 387:1909\u20131920","journal-title":"Lancet"},{"key":"342_CR20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51\u201360","journal-title":"Cancer Treat Rev"},{"key":"342_CR21","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1055\/s-0042-107437","volume":"141","author":"HC Spangenberg","year":"2016","unstructured":"Spangenberg HC (2016) Drug induced liver injury. Dtsch Med Wochenschr 141:1688\u20131691","journal-title":"Dtsch Med Wochenschr"},{"key":"342_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2016.10.016","author":"E Sulava","year":"2016","unstructured":"Sulava E, Bergin S, Long B, Koyfman A (2016) Elevated liver enzymes: emergency department-focused management. J\u00a0Emerg Med. doi: 10.1016\/j.jemermed.2016.10.016","journal-title":"J Emerg Med"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-017-0342-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-017-0342-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-017-0342-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T11:33:02Z","timestamp":1498390382000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-017-0342-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,28]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["342"],"URL":"https:\/\/doi.org\/10.1007\/s00120-017-0342-3","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,28]]}}}